Altria relies on cigarettes as vapes face bans, flavors grow and on! competes with ZYN, with low multiple and 7.5% dividend appeal. Read why MO stock is a buy.
FDA scientists appear poised to sign off on the company’s proposal, according to a preliminary review posted by the agency ...
In late 2025, the FDA granted marketing authorization for six on! PLUS nicotine pouch products made by Altria Group’s Helix Innovations subsidiary under its new expedited Premarket Tobacco Product ...
MO is making steady progress in the smoke-free transition, with oral nicotine gaining traction as it reshapes the business ...
Altria Group (MO) shares continued gains for seven straight sessions, as the stock closed 0.42% higher at $61.84 on Friday. The Marlboro maker’s shares gained over 10% in the preceding six sessions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results